|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����Ī˾ |
|
ƥ����Ī˾ |
|
����Ӧ�� |
| ��������������� | |
|
�ƺ�ɺ |
|
��һԪ |
| PubMed | |
|
Article by �ƺ�ɺ |
|
Article by ��һԪ |
����Ī˾��ƥ����Ī˾�ľֲ�Ӧ��
�ƺ�ɺ1, ��һԪ2
1. ����ʡ��ҽԺƤ����, �Ϸ�230001;
2. ����ҽ�ƴ�ѧ������һҽԺƤ����
�ֲ�Ӧ�õ�����Ī˾����ƥ����Ī˾˪�������µĸƵ�����ø���Ƽ�����Ϊ�ֲ����ߵ��ڼ�������Ӧ��Ƥ�����ơ���Ϊ����ҩ��dz���ȫ�ͽϺ���Ч���ص�,ʹ���dz�Ϊ�������Ƥ���������������ĺ�ѡҩ��ѷ�������ױ������dz�Ӧ������Ӧ��Ƥ����,�п�������м����֬����Ƥ�ס���ƽ̦������������
1. ����ʡ��ҽԺƤ����, �Ϸ�230001;
2. ����ҽ�ƴ�ѧ������һҽԺƤ����
1. ����ʡ��ҽԺƤ����, �Ϸ�230001;
2. ����ҽ�ƴ�ѧ������һҽԺƤ����
[2] Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel,SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg, 2001, 20(4):233-241.
[3] Boguniewicz M, Leung DY. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg, 2001,20(4):217-225.
[4] Bergman J, Rico MJ. Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg, 2001, 20 (4):250-259.
[5] Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehiclecontrolled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol, 1998, 102(4 Pt 1):637-644.
[6] Eichenfield LF, Lucky AW, Boguniewicz M,et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol, 2002, 46(4):495-504.
[7] Reitamo S, Van Leent E J, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol, 2002, 109(3):539-546.
[8] Ling MR. Topical tacrolimus and pimecrolimus:future directions. Semin Cutan Med Surg, 2001, 20(4):268-274.
[9] Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol, 1998, 139(6):992-996.
[10] Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol, 1998, 134(9):1101-1102.
[11] McElwee KJ, Rushton DH, Trachy R, et al. Topical FK506:a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br J Dermatol, 1997, 137(4):491-497.
[12] Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol, 1994,102(2):160-164.
[13] Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease:a case series of 18 patients. Arch Dermatol, 2001, 137(9):1202-1206.